Lorabid
"Sometimes the juice ain't worth the squeeze... especially when combining grapefruit with medicines.
While it can be part of a balanced and nutritious diet, grapefruit can have serious consequences when taken with certain medications. Cu"...
Lorabid
Please Note: This Brand Name drug is no longer available in the US.(Generic versions may still be available.)
Lorabid Side Effects Center
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Lorabid in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
- diarrhea that is watery or bloody;
- seizure (convulsions);
- fever, sore throat, and joint pain with a severe blistering, peeling, and red skin rash;
- easy bruising or bleeding, unusual weakness; or
- skin rash, bruising, severe tingling, numbness, pain, muscle weakness.
Less serious side effects may include:
- mild itching or skin rash;
- mild nausea, vomiting, stomach pain, loss of appetite;
- warmth, redness, or tingling under your skin;
- headache;
- dizziness, drowsiness; or
- vaginal itching or discharge.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect.
Read the entire detailed patient monograph for Lorabid (Loracarbef) »
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Lorabid FDA Prescribing Information: Side Effects
(Adverse Reactions)
SIDE EFFECTS
The nature of adverse reactions to loracarbef are similar to those observed with orally administered b-lactam antimicrobials. The majority of adverse reactions observed in clinical trials were of a mild and transient nature; 1.5% of patients discontinued therapy because of drug-related adverse reactions. No one reaction requiring discontinuation accounted for >0.03% of the total patient population; however, of those reactions resulting in discontinuation, gastrointestinal events (diarrhea and abdominal pain) and skin rashes predominated.
All Patients
The following adverse events, irrespective of relationship to drug, have been reported following the use of loracarbef in clinical trials. Incidence rates (combined for all dosing regimens and dosage forms) were less than 1% for the total patient population, except as otherwise noted:
Gastrointestinal: The most commonly observed adverse reactions were related to the gastrointestinal system. The incidence of gastrointestinal adverse reactions increased in patients treated with higher doses. Individual event rates included diarrhea, 4.1%; nausea, 1.9%; vomiting 1.4%; abdominal pain, 1.4%; and anorexia.
Hypersensitivity: Hypersensitivity reactions including, skin rashes (1.2%), urticaria, pruritus, and erythema multiforme.
Central Nervous System: Headache (2.9%), somnolence, nervousness, insomnia, and dizziness.
Hemic and Lymphatic Systems: Transient thrombocytopenia, leukopenia, and eosinophilia.
Hepatic: Transient elevations in AST (SGOT), ALT (SGPT), and alkaline phosphatase.
Renal: Transient elevations in BUN and creatinine.
Cardiovascular System: Vasodilatation.
Genitourinary: Vaginitis (1.3%), vaginal moniliasis (1.1%).
As with other b-lactam antibiotics, the following potentially severe adverse experiences have been reported rarely with loracarbef in worldwide post-marketing surveillance: anaphylaxis, hepatic dysfunction including cholestasis, prolongation of the prothrombin time with clinical bleeding in patients taking anticoagulants, and Stevens-Johnson syndrome.
Pediatric Patients
The incidences of several adverse events, irrespective of relationship to drug, following treatment with loracarbef were significantly different in the pediatric population and the adult population as follows (TABLE 12):
| TABLE 12 | ||
| Event | Pediatric | Adult |
|---|---|---|
| Diarrhea | 5.8% | 3.6% |
| Headache | 0.9% | 3.2% |
| Rhinitis | 6.3% | 1.6% |
| Nausea | 0.0% | 2.5% |
| Rash | 2.9% | 0.7% |
| Vomiting | 3.3% | 0.5% |
| Somnolence | 2.1% | 0.4% |
| Anorexia | 2.3% | 0.3% |
b-Lactam Antimicrobial Class Labeling
The following adverse reactions and altered laboratory test results have been reported in patients treated with b-lactam antibiotics:
Adverse Reactions: Allergic reactions, aplastic anemia, hemolytic anemia, hemorrhage, agranulocytosis, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy. As with other b-lactam antibiotics, serum sickness-like reactions have been reported rarely with loracarbef.
Several b-lactam antibiotics have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy should occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Altered Laboratory Tests: Increased prothrombin time, positive direct Coombs' test, elevated LDH, pancytopenia, and neutropenia.
Read the entire FDA prescribing information for Lorabid (Loracarbef) »
Additional Lorabid Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
